| Nome |
# |
|
Soluble angiogenic factors: implications for chronic myeloproliferative disorders, file e309ade5-7920-3969-e053-3a05fe0a2c94
|
1.087
|
|
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications, file e309ade5-791e-3969-e053-3a05fe0a2c94
|
49
|
|
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases, file 671ab7e6-8098-4f67-8828-67dd869b9e0e
|
30
|
|
Markers of endothelial and platelet status in patients with essential thrombocytemia and polycythemia vera, file e309ade5-7927-3969-e053-3a05fe0a2c94
|
28
|
|
Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications, file e309ade5-7935-3969-e053-3a05fe0a2c94
|
20
|
|
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial, file 207805f5-9d72-4c3b-8e59-35040fc71771
|
18
|
|
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer, file 45f77a24-7b44-4983-a51b-9a16f697b670
|
14
|
|
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center, file bfc93196-11f1-43d0-972b-4038e646d2e9
|
14
|
|
Methimazole-induced agranulocytosis and quick recovery with G-CSF: case report, file e309ade5-7922-3969-e053-3a05fe0a2c94
|
14
|
|
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy, file 1c596e71-b0f8-4b51-b76b-373a5b29f886
|
12
|
|
The emerging role of cancer nanotechnology in the panorama of sarcoma, file 87ee8e9d-b480-4133-91ec-3e3a29dafc9b
|
12
|
|
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines, file a0f39a39-d30c-42df-8bf3-0f28b424ea93
|
12
|
|
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study, file e309ade5-7abb-3969-e053-3a05fe0a2c94
|
12
|
|
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme, file e309ade5-65e8-3969-e053-3a05fe0a2c94
|
11
|
|
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival, file e309ade5-7acc-3969-e053-3a05fe0a2c94
|
11
|
|
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era, file 213fd534-22bf-4f34-9d7f-ce7187befa83
|
10
|
|
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis, file 23cbf824-e9f4-4f6b-ad07-4d6bed902fe1
|
10
|
|
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy, file d71a499e-d14d-4fd6-9fd8-33f56089c8f3
|
10
|
|
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870.893, file 33dfcb07-08a8-4e18-88be-2b890c16e98d
|
9
|
|
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer, file a278602d-c6e1-45d4-ac3a-165653e5edca
|
9
|
|
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients, file e309ade5-674f-3969-e053-3a05fe0a2c94
|
9
|
|
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012, file e309ade5-7ab9-3969-e053-3a05fe0a2c94
|
9
|
|
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line, file e309ade5-7ace-3969-e053-3a05fe0a2c94
|
9
|
|
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?, file 4f677aec-5fa8-4af2-ae79-21f44fec3d88
|
8
|
|
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC, file e309ade5-6753-3969-e053-3a05fe0a2c94
|
8
|
|
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era, file e309ade5-65ea-3969-e053-3a05fe0a2c94
|
7
|
|
Circulating haemopoietic and endothelial cells are decreased in COPD, file e309ade5-7aba-3969-e053-3a05fe0a2c94
|
7
|
|
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation, file e309ade5-7abc-3969-e053-3a05fe0a2c94
|
7
|
|
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy, file e309ade5-7acd-3969-e053-3a05fe0a2c94
|
7
|
|
Challenges in lung cancer therapy during the COVID-19 pandemic, file 825c5430-7d3a-4c40-8054-83742b888b03
|
6
|
|
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis, file 87e51c42-e8f7-482c-9045-982006388c92
|
6
|
|
COVID and Lung Cancer, file 954c0827-4b5e-4181-baff-d4d9750515fc
|
6
|
|
Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies, file e985b474-c6b6-4c73-80cb-3de737b3dd83
|
6
|
|
Challenges in lung cancer therapy during the COVID-19 pandemic, file e309ade5-6750-3969-e053-3a05fe0a2c94
|
5
|
|
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy, file e309ade5-6752-3969-e053-3a05fe0a2c94
|
5
|
|
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy, file e309ade5-792e-3969-e053-3a05fe0a2c94
|
4
|
|
Targeting of HLA-DR molecules transduces agonistic functional signals in Cutaneous melanoma, file e309ade5-792f-3969-e053-3a05fe0a2c94
|
4
|
|
Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukemia and essential thrombocytaemia, file e309ade5-7abd-3969-e053-3a05fe0a2c94
|
4
|
|
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial, file e309ade5-7ac2-3969-e053-3a05fe0a2c94
|
4
|
|
Profilo lipidico nelle neoplasie ematologiche [Lipid profile in haematological malignancies], file e309ade5-7acb-3969-e053-3a05fe0a2c94
|
4
|
|
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study, file c00df718-567e-44ca-b271-0675d2977719
|
3
|
|
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab, file e309ade5-674d-3969-e053-3a05fe0a2c94
|
3
|
|
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences, file e309ade5-7ac3-3969-e053-3a05fe0a2c94
|
3
|
|
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study, file e309ade5-7ac4-3969-e053-3a05fe0a2c94
|
3
|
|
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), file e309ade5-7ac8-3969-e053-3a05fe0a2c94
|
3
|
|
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy, file 1f2f6901-83a1-4f58-aaab-0a9a1ae06bac
|
2
|
|
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study, file a2f21a49-7ac9-41d5-95aa-e7e8456e6f75
|
2
|
|
Recombinant transmembrane CD59 (CD59-TM) confers complement resistence to GPI-anchored protein detective melanoma cells., file e309ade5-65e9-3969-e053-3a05fe0a2c94
|
2
|
|
Differential levels of solubile angiopoietin-2 and Tie-2 in patients with haematological malignancies, file e309ade5-6754-3969-e053-3a05fe0a2c94
|
2
|
|
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy, file e309ade5-6755-3969-e053-3a05fe0a2c94
|
2
|
|
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implication, file e309ade5-6756-3969-e053-3a05fe0a2c94
|
2
|
|
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study, file e309ade5-7795-3969-e053-3a05fe0a2c94
|
2
|
|
Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT), file e309ade5-791d-3969-e053-3a05fe0a2c94
|
2
|
|
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge, file e309ade5-791f-3969-e053-3a05fe0a2c94
|
2
|
|
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study, file e309ade5-7924-3969-e053-3a05fe0a2c94
|
2
|
|
Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin, file e309ade5-7929-3969-e053-3a05fe0a2c94
|
2
|
|
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain, file e309ade5-792c-3969-e053-3a05fe0a2c94
|
2
|
|
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study, file e309ade5-7930-3969-e053-3a05fe0a2c94
|
2
|
|
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010, file e309ade5-7932-3969-e053-3a05fe0a2c94
|
2
|
|
Differential levels of solubile Endoglin (CD105) in myeloid malignancies, file e309ade5-7937-3969-e053-3a05fe0a2c94
|
2
|
|
Levels of solubile angiogenin in chronic myeloid malignancies: clinical implications, file e309ade5-7938-3969-e053-3a05fe0a2c94
|
2
|
|
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases, file e309ade5-7ab8-3969-e053-3a05fe0a2c94
|
2
|
|
Epigenetically regulated clonal heretability of CTA expression profiles in human melanoma, file e309ade5-7ac0-3969-e053-3a05fe0a2c94
|
2
|
|
Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy), file e309ade5-7ac1-3969-e053-3a05fe0a2c94
|
2
|
|
Thymosin α1 in melanoma from the clinical trial setting to the daily practice and beyond, file e309ade5-7ac5-3969-e053-3a05fe0a2c94
|
2
|
|
L'ipersplenismo: Attualità e prospettive [Hypersplenism: Current status and perspectives], file e309ade5-7ac7-3969-e053-3a05fe0a2c94
|
2
|
|
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications, file e309ade5-7ac9-3969-e053-3a05fe0a2c94
|
2
|
|
The future of mesothelioma treatment: time to shift gear, file 07c1c65f-4f61-42dd-8d6c-6fb6a1c50f81
|
1
|
|
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream, file 4b71465c-38cd-4c1f-a093-7e9b355df7ab
|
1
|
|
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study, file 5229cae5-6ee5-4c34-8dc2-b08854b9ee44
|
1
|
|
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial, file 6f51dd76-8091-4a8e-925b-31b71c5d7c76
|
1
|
|
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial, file 9da2eb2c-fc33-47c8-8870-0684c30e245a
|
1
|
|
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial, file e309ade5-4b4a-3969-e053-3a05fe0a2c94
|
1
|
|
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy, file e309ade5-674e-3969-e053-3a05fe0a2c94
|
1
|
|
Expression and regulation of the B7-H3 receptor in human mesothelial and mesothelioma cells: a novel target for immunotherapeutic applications, file e309ade5-6751-3969-e053-3a05fe0a2c94
|
1
|
|
Biomarkers for immune checkpoint inhibitors--authors' reply, file e309ade5-6757-3969-e053-3a05fe0a2c94
|
1
|
|
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?, file e309ade5-6758-3969-e053-3a05fe0a2c94
|
1
|
|
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?, file e309ade5-6759-3969-e053-3a05fe0a2c94
|
1
|
|
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program, file e309ade5-7796-3969-e053-3a05fe0a2c94
|
1
|
|
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014, file e309ade5-7921-3969-e053-3a05fe0a2c94
|
1
|
|
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015, file e309ade5-7923-3969-e053-3a05fe0a2c94
|
1
|
|
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25, file e309ade5-7926-3969-e053-3a05fe0a2c94
|
1
|
|
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial, file e309ade5-7928-3969-e053-3a05fe0a2c94
|
1
|
|
New Horizons from Immunotherapy in Malignant Pleural Mesothelioma, file e309ade5-792a-3969-e053-3a05fe0a2c94
|
1
|
|
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial, file e309ade5-792b-3969-e053-3a05fe0a2c94
|
1
|
|
Immunotherapy of brain metastases: breaking a “dogma”, file e309ade5-792d-3969-e053-3a05fe0a2c94
|
1
|
|
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer, file e309ade5-7931-3969-e053-3a05fe0a2c94
|
1
|
|
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population, file e309ade5-7933-3969-e053-3a05fe0a2c94
|
1
|
|
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma, file e309ade5-7936-3969-e053-3a05fe0a2c94
|
1
|
|
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab, file e309ade5-7abe-3969-e053-3a05fe0a2c94
|
1
|
|
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients, file e309ade5-7abf-3969-e053-3a05fe0a2c94
|
1
|
|
Immune checkpoint blockade in malignant mesothelioma, file e309ade5-7aca-3969-e053-3a05fe0a2c94
|
1
|
|
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study, file ea2af2c7-31ea-43f3-984c-da8a7117b10f
|
1
|
|
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge, file fd184dd0-c83d-4d92-8103-e80324607e3f
|
1
|
| Totale |
1.603 |